Share

EyePoint Pharmaceuticals Inc. - news published 365 - readings 2.765

BACK
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

PDF Version WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, will participate in a fireside ch ...

Continue reading
27.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer EyePoint Pharmaceuticals Inc. published this content on March 17, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 17, 2025 at 11:12:56.498 .

Continue reading
17.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of financial condition and results of operations should be read in conjunction with our audited Consolidated Financial Statements and related Notes beginning on page F-1 of this Annual Report on Form 10-K. This discussion contains forward-looking statemen ...

Continue reading
06.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer EyePoint Pharmaceuticals Inc. published this content on March 05, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 05, 2025 at 12:09:26.227 .

Continue reading
05.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (Form 8-K)

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule - - Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints - - $371 million ...

Continue reading
05.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

Investor Presentation of EyePoint Pharmaceuticals, Inc. dated March 4, 2025 (Form 8-K)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer EyePoint Pharmaceuticals Inc. published this content on March 04, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 04, 2025 at 14:02:32.590 .

Continue reading
04.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint Announces Participation at Upcoming Investor Conferences

PDF Version WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: Leerink Partners Glo ...

Continue reading
04.03.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer EyePoint Pharmaceuticals Inc. published this content on February 26, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 26, 2025 at 12:10:24.254 .

Continue reading
26.02.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer EyePoint Pharmaceuticals Inc. published this content on February 25, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 25, 2025 at 12:10:49.535 .

Continue reading
25.02.2025
EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc.

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer EyePoint Pharmaceuticals Inc. published this content on February 05, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 05, 2025 at 12:11:17.252 .

Continue reading
05.02.2025